The World Health Organization (WHO) recently declared the COVID-19 pandemic, which is currently considered one of the key public health threats worldwide. The number of infections continues to rise, and the SARS-CoV-2 virus is causing increasing concern.
In this regard, we invite you to participate in the clinical trial entitled "A multicenter, open-label, randomized, non-commercial study aimed at evaluating the efficacy and safety of chloroquine phosphate in ambulatory treatment of COVID-19 in combination with telemedicine care among individuals infected with SARS-CoV2 at risk of developing complications in order to reduce the risk of hospitalization associated with COVID-19 and death." The main objective of this study is to determine whether chloroquine phosphate used in home settings (during quarantine) in combination with telemedicine care in patients with SARS-CoV-2 infection at an early stage of infection not requiring hospitalization and at increased risk of complications in the course of COVID-19, compared to standard treatment, prevents hospitalization due to COVID-19 and death in a 15-day observation.
To start entering patient observation data, please log in.